{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.39","value":"46.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"131"}],"units":"Participants"}],"title":"Baseline Percent Tissue Fat Mass"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.73","value":"-1.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"}],"title":"Change from Baseline in Percent Tissue Fat Mass at Week 22"}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"}],"units":"Participants"}],"description":"Tissue fat mass was measured by DXA scan.","dispersionType":"Standard Deviation","groups":[{"description":"Patients will receive relacorilant increased sequentially from 100 mg once daily to a maximum dose of 400 mg once daily.\n\nRelacorilant: Relacorilant is supplied as 100 mg capsules for oral dosing.","id":"OG000","title":"Relacorilant (OL Phase)"}],"paramType":"MEAN","populationDescription":"The analysis population was patients in the modified ITT-OL (mITT-OL) Population including all enrolled patients who received at least 1 dose of study drug and had at least 1 postbaseline efficacy assessment.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 22 (end of OL Phase)","title":"Change in Percent Tissue Fat Mass During the OL Phase","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Percentage"}